Diagnostic and prognostic role of HBME-1, galectin-3, and β-catenin in poorly differentiated and anaplastic thyroid carcinomas

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 3, 2013, Pages 237-241

  Rossi, Esther D ^a   Straccia, Patrizia ^a   Palumbo, Marianna ^a   Stigliano, Egidio ^a   Revelli, Luca ^b   Lombardi, Celestino P ^b   Santeusanio, Giuseppe ^c   Pontecorvi, Alfredo ^d   Fadda, Guido ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Division of Endocrinology   (Italy)

^c UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

anaplastic thyroid carcinoma; immunohistochemistry; poorly differentiated thyroid carcinoma; prognosis

Indexed keywords

BETA CATENIN; GALECTIN 3; HBME 1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OUTCOME ASSESSMENT; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA; THYROID METASTASIS; TUMOR INVASION;

ADULT; AGED; BETA CATENIN; CARCINOMA; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; DIAGNOSIS, DIFFERENTIAL; FEMALE; GALECTIN 3; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877000331     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182688d0f     Document Type: Article

References (32)

1. Hedinger C, Williams ED, Sobin LH. Histologial typing of thyroid tumours. International Histologic Classification of Tumours. 2nd ed. Berlin: World Health Organization-Springer Verlag; 1998:13-14.
2. Carcangiu ML, Zampi G, Rosai J. Poorly differentiated ("insular") thyroid carcinoma. Am J Surg Pathol. 1984;8:655-668.
3. Volante M, Rapa I, Gandhi M, et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab. 2009;94:4735-4741.
4. Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31:1256-1264.
5. Volante M, Rapa I, Papotti M. Poorly differentiated thyroid carcinoma: diagnostic features and controversial issues. Endocr Pathol. 2008;19:150-155.
6. Tallini G. Poorly differentiated thyroid carcinoma. Are we there yet? Endocr Pathol. 2011;22:190-194.
7. Rocha AS, Soares P, Fonseca E, et al. E-cadherin loss rather b-catenin alteration is a common feature of poorly differentiated thyroid carcinomas. Histopathology. 2003;42:580-587.
8. Garcia-Rostan G, Camp RL, Herrero A, et al. b-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol. 2001;158:987-996.
9. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinoma and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2008;88:5399-5404.
10. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch. 2004;444:572-576.
11. Kazaure HS, Roman SA, Sosa JA. Insular thyroid cancer. A population-level analysis of patient characteristics and predictors of survival. Cancer. 2012;118:3260-3267.
12. Dettmer M, Schmitt A, Steinert H, et al. Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed? Am J Surg Pathol. 2011;35:1866-1872.
13. Siironen P, Hagstrom J, Maenpaa HO, et al. Anaplastic and Poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients. Oncology. 2010;79: 400-408.
14. Sanders EM, LiVolsi VA, Brierley J, et al. An evidence-based review of poorly differentiated thyroid cancer. World J Surg. 2007;31: 934-945.
15. Simpson WJ. Anaplastic thyroid carcinoma: a new approach. Can J Surg. 1980;23:25-27.
16. Torregrossa L, Giannini R, Borrelli N, et al. CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas. Mod Pathol. 2011;1-10.
17. Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinoma. Endocr Pathol. 2004;15:319-327.
18. Rossi ED, Raffaelli M, Mule' A, et al. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology. 2006;48:795-800.
19. Rossi ED, Raffaelli M, Minimo C, et al. Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fineneedle aspiration biopsies. Cancer Cytopathol. 2005;105:87-95.
20. American Joint Commission on Cancer. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FI, Trotti A, eds. 7th ed. 2010;87-96.
21. Ashfaq R, Vuitch F, Delgado R, et al. Papillary and follicular thyroid carcinomas with an insular component. Cancer. 1994;73: 416-423.
22. Jung TS, Kim TY, Kim KW, et al. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. Endocr J. 2007;54: 265-274.
23. Rufini V, Salvatori M, Fadda G, et al. Thyroid carcinomas with a variable insular component. Cancer. 2007;110:1209-1217.
24. Takano T, Ito Y, Hirokawa M, et al. V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br J Cancer. 2007;96:1549-1553.
25. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007; 92:4085-4092.
26. Herrmann ME, LiVolsi VA, Pasha TL, et al. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med. 2002;126:710-713.
27. Miettinen M, Kovatich AJ. HBME-1 monoclonal antibody useful in the differential diagnosis of mesothelioma, adenocarcinoma and soft tissue and bone tumors. Appl Immunohistochem. 1995;3:115-122.
28. Cheung CC, Ezzat S, Freeman JL, et al. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol. 2001;14: 338-342.
29. Garcia-Rostan G, Tallini G, Herrero A, et al. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res. 1999;59:1811-1815.
30. Scheumann GF, Hoang-Vu C, Cetin Y. Clinical significance of E-Cadherin as a prognostic marker in thyroid carcinomas. J Clin Endocrinol Metab. 1995;80:2168-2172.
31. Takeichi M. Cadherin cell adhesion receptors as morphogenetic regulator. Science. 1991;22:1451-1455.
32. Papotti M, Rodriguez J, De Pompa R, et al. Galectin-3 and HBME- 1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol. 2005; 18:541-546.